Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 8/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.36 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4584508 | 0.82 | TSHR (0.36) | ADRB3TSHRPDE4AALDH1A1PTK2 | |
| SCHEMBL4584511 | 0.82 | TSHR (0.36) | ADRB3TSHRPDE4AALDH1A1PTK2 | |
| SCHEMBL6136677 | 0.79 | ALOX15 (0.37) | ADRB3ADRB1ADRB2PDE4AALDH1A1 | |
| SCHEMBL6136680 | 0.79 | ALOX15 (0.37) | ADRB3ADRB1ADRB2PDE4AALDH1A1 | |
| SCHEMBL6136674 | 0.79 | ALOX15 (0.37) | ADRB3ADRB1ADRB2PDE4AALDH1A1 | |
| SCHEMBL6328475 | 0.73 | ADRB3 (0.50) | ADRB3ADRB1ADRB2ALDH1A1MEN1 | |
| SCHEMBL6328477 | 0.73 | ADRB3 (0.50) | ADRB3ADRB1ADRB2ALDH1A1MEN1 | |
| SCHEMBL4585225 | 0.69 | SMN1; SMN2 (0.39) | PDE4AALDH1A1PTK2MEN1KMT2A | |
| SCHEMBL4585228 | 0.69 | SMN1; SMN2 (0.39) | PDE4AALDH1A1PTK2MEN1KMT2A | |
| SCHEMBL6342245 | 0.67 | CYP3A4 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417060-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2008-08-26 | — | — | US | disclosed |
| EP-1697301-A2 | AMINOALCOHOL DERIVATIVES | Astellas Pharma Inc. (JP) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005061433-A2 | AMINOALCOHOL DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2005-07-07 | — | — | WO | disclosed |
| US-20050137236-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137236-A1 | Aminoalcohol derivatives | GPR39, PRMT9, CHRM2 | ADRB3 86/4885TSHR 2617/4885ADRB1 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.